DOCKET NO.: CHEM0005US.P1/ISIS-5782 PATENT

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Muthiah Manoharan Confirmation No.: 4943
Application No.: 10/700971 Group Art Unit: 1635
Filing Date: November 4, 2003 Examiner: Sean McGarry

For: Conjugated Oligomeric Compounds and Their Use in Gene Modulation

Filed Via EFS

#### INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

### IDS Filed Under 37 CFR 1.97(b)

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

# IDS filed Under 37 CFR 1.97(c)

In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

Certification in Accordance with § 1.97(e) is attached; or
The fee of \$180.00 as set forth in § 1.17(p) is attached.

# DOCKET NO.: CHEM0005US.P1/ISIS-5782

#### $\boxtimes$ IDS filed Under 37 CFR 1.97(d)

In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

#### CONTENT OF IDS PURSUANT TO 37 CFR 1.98

Document

$\boxtimes$	Copies of reference numbers 9-12 listed on the attached Form PTO-1449 or Substitute Form PTO-1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(iii).					
	Copies of reference r PTO-1449 are enclose		listed on the attac	ched Form PTO-1449 or Substitute Form		
	•	d to the U.S.	Patent and Tradem	ubmitted because they were previously ark Office in patent application number er 35 U.S.C. § 120 has been made in the		
		references is	sufficiently earlier	is not available. However, the year of than the effective US filing date and any sublication is not in issue pursuant to 37		
REFERENCES IN A LANGUAGE OTHER THAN ENGLISH						
	of the relevance of below, the documer	the documen	t was incorporated fied in a foreign co	rage. Accordingly, a concise explanation in the specification passages identified mmunication as identified below or an ovided as indicated below.		
Foreign Language Cite		Cite No.	Pages of F	Reference in Specification or		

Relevance of Document

DOCKET NO.: CHEM0005US.P1/ISIS-5782 PATENT

Foreign Language Document	Cite No.	English Language Counterpart	Cite No.

# □ CERTIFICATION IN ACCORDANCE WITH § 1.97(e)

I hereby certify that:

L	■ Each item of information contained in this information disclosure statement was first cited in
	any communication from a foreign patent office in a counterpart foreign application not more
	than three months prior to the filing of this information disclosure statement.

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this information disclosure statement.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

Date: April 25, 2012 /John A. Harrelson, Jr./ John A. Harrelson, Jr.

Registration No. 42637

WOODCOCK WASHBURN LLP Cira Centre 2929 Arch Street, 12th Floor

Philadelphia, PA 19104-2891 Telephone: (215) 568-3100 Facsimile: (215) 568-3439